Blockade of vascular endothelial growth factor-A/receptor 2 exhibits a protective effect on angiotensin-II stimulated podocytes

Liu,Xiangchun; Zhang,Hong; Wang,Qun; Yu,Kezhou; Wang,Rong; Sun,Jing

doi:10.3892/mmr.2015.3911

Blockade of vascular endothelial growth factor-A/receptor 2 exhibits a protective effect on angiotensin-II stimulated podocytes

Authors:
- Xiangchun Liu
- Hong Zhang
- Qun Wang
- Kezhou Yu
- Rong Wang
- Jing Sun
View Affiliations

Affiliations: Department of Nephrology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: June 11, 2015 https://doi.org/10.3892/mmr.2015.3911
Pages: 4340-4345

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vascular endothelial growth factor (VEGF) and Angiotensin II (Ang-II) are important in glomerulosclerosis, which is one of the main causes of chronic kidney disease. Previous studies have demonstrated that angiotensin type 1 receptor blocker (ARB) can inhibit the synthesis of VEGF mediated by Ang‑II and can effectively treat diabetic nephropathy. In the present study, the expression of VEGF and its receptors (VEGFR1/VEGFR2) was examined in Ang‑II stimulated podocytes, which were treated with SU5416, a specific VEGFR2 inhibitor. The protein expression of synaptopodin, VEGFR1/2, phosphorylated VEGFR2 and extracellular signal‑regulated kinases (ERK) was assessed by western blot analysis. The mRNA expression of transforming growth factor (TGF)‑β1 was examined by reverse transcription‑quantitative polymerase chain reaction. It was observed that Ang‑II increased the expression of VEGF‑A and VEGFR2. Simultaneously, the increased expression of phosphorylated (p‑)VEGFR2 and p‑ERK induced by Ang‑II was downregulated by SU5416. SU5416 can decrease the expression of synaptopodin and increase the expression of TGF‑β1 induced by Ang‑II as well as ARB treatment. The expression of VEGFR1 remained unchanged by either Ang‑II or SU5416 treatment. However, the normal podocytes administered SU5416 alone showed low levels of synaptopodin and high expression of TGF‑β1 compared with the control. In conclusion, VEGF‑A/VEGFR2 may be essential for podocytes in a normal state. It is suggested that blockade of VEGF‑A/VEGFR2 may exhibit a protective effect on Ang-II stimulated podocytes.

View Figures

View References

1	Ma J, Rossini M, Yang HC, Zuo Y, Fogo AB and Ichikawa I: Effects of podocyte injury on glomerular development. Pediatr Res. 62:417–421. 2007. View Article : Google Scholar : PubMed/NCBI
2	Kim NH, Oh JH, Seo JA, et al: Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int. 67:167–177. 2005. View Article : Google Scholar
3	Bates DO and Curry FE: Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels. Am J Physiol. 271:H2520–H2528. 1996.PubMed/NCBI
4	Siemann DW, Brazelle WD and Jürgensmeier JM: The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts. Int J Radiat Oncol Biol Phys. 73:897–903. 2009. View Article : Google Scholar : PubMed/NCBI
5	Maeshima Y and Makino H: Angiogenesis and chronic kidney disease. Fibrogenesis Tissue Repair. 3:13–30. 2010. View Article : Google Scholar : PubMed/NCBI
6	Foster RR, Hole R, Anderson K, et al: Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol. 284:F1263–F1273. 2003. View Article : Google Scholar : PubMed/NCBI
7	Baharivand N, Zarghami N, Panahi F, et al: Relationship between vitreous and serum vascular endothelial growth factor levels, control of diabetes and microalbuminuria in proliferative diabetic retinopathy. Clin Ophthalmol. 6:185–191. 2012.PubMed/NCBI
8	Ho C, Hsu YC, Tseng CC, et al: Simvastatin alleviates diabetes-induced VEGF-mediated nephropathy via the modulation of Ras signaling pathway. Ren Fail. 30:557–565. 2008. View Article : Google Scholar : PubMed/NCBI
9	Doi K, Leelahavanichkul A, Hu X, et al: Pre-existing renal disease promotes sepsis-induced acute kidney injury and worsens outcome. Kidney Int. 74:1017–1025. 2008. View Article : Google Scholar : PubMed/NCBI
10	Celletti FL, Waugh JM, Amabile PG, et al: Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 7:425–429. 2001. View Article : Google Scholar : PubMed/NCBI
11	Ferrara N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 29(Suppl 16): 10–14. 2002. View Article : Google Scholar
12	Sugimoto H, Hamano Y, Charytan D, et al: Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 278:12605–12608. 2003. View Article : Google Scholar : PubMed/NCBI
13	Eremina V, Jefferson JA, Kowalewska J, et al: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 358:1129–1136. 2008. View Article : Google Scholar : PubMed/NCBI
14	Shankland SJ, Pippin JW, Reiser J and Mundel P: Podocytes in culture: past, present, and future. Kidney Int. 72:26–36. 2007. View Article : Google Scholar : PubMed/NCBI
15	Krtil J, Pláteník J, Kazderová M, et al: Culture methods of glomerular podocytes. Kidney Blood Press Res. 30:162–174. 2007. View Article : Google Scholar : PubMed/NCBI
16	Liang XB, Ma LJ, Naito T, et al: Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth. J Am Soc Nephrol. 17:1886–1895. 2006. View Article : Google Scholar : PubMed/NCBI
17	Mezrich JD, Nguyen LP, Kennedy G, et al: SU5416, a VEGF receptor inhibitor and ligand of the AHR, represents a new alternative for immunomodulation. PLoS ONE. 7:e445472012. View Article : Google Scholar : PubMed/NCBI
18	Westenskow PD, Kurihara T, Aguilar E, et al: Ras pathway inhibtion prevents neovascularization by repressing endothelial cell sprouting. J Clin Invest. 123:4900–4908. 2013. View Article : Google Scholar : PubMed/NCBI
19	Veron D, Bertuccio CA, Marlier A, et al: Podocyte vascular endothelial growth factor (Vegf₁₆₄) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia. 54:1227–1241. 2011. View Article : Google Scholar : PubMed/NCBI
20	Nasu T, Maeshima Y, Kinomura M, et al: Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy. Diabetes. 58:2365–2375. 2009. View Article : Google Scholar : PubMed/NCBI
21	Kim W, Moon SO, Lee SY, et al: COMP-angiopoietin-1 ameliorates renal fibrosis in a unilateral ureteral obstruction model. J Am Soc Nephrol. 17:2474–2483. 2006. View Article : Google Scholar : PubMed/NCBI
22	Eremina V and Quaggin SE: The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens. 13:9–15. 2004. View Article : Google Scholar : PubMed/NCBI
23	Hohenstein B, Colin M, Foellmer C, et al: Autocrine VEGF-R loop on podocytes during glomerulonephritis in humans. Nephrol Dial Transplant. 25:3170–3180. 2010. View Article : Google Scholar : PubMed/NCBI
24	Yanagida-Asanuma E1, Asanuma K, Kim K, et al: Synaptopodin protects against proteinuria by disrupting Cdc42:IRSp53: Mena signaling complexes in kidney podocytes. Am J Pathol. 171:415–427. 2007. View Article : Google Scholar : PubMed/NCBI
25	de Zoysa JR and Topham PS: Podocyte biology in human disease. Nephrology (Carlton). 10:362–367. 2005. View Article : Google Scholar
26	Asanuma K, Kim K, Oh J, et al: Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner. J Clin Invest. 115:1188–1198. 2005. View Article : Google Scholar : PubMed/NCBI
27	Faul C, Asanuma K, Yanagida-Asanuma E, Kim K and Mundel P: Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol. 17:428–437. 2007. View Article : Google Scholar : PubMed/NCBI
28	Faul C, Donnelly M, Merscher-Gomez S, et al: The actin cytoskeleton of kidney podocytes is a direct target of the anti-proteinuric effect of cyclosporine A. Nat Med. 14:931–938. 2008. View Article : Google Scholar : PubMed/NCBI
29	Izzedine H, Massard C, Spano JP, et al: VEGF signaling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer. 46:439–448. 2010. View Article : Google Scholar
30	Ichikawa I, Ma J, Motojima M and Matsusaka T: Podocyte damage damages podocytes: autonomous vicious cycle that drives local spread of glomerular sclerosis. Curr Opin Nephrol Hypertens. 14:205–210. 2005. View Article : Google Scholar : PubMed/NCBI
31	Zhao Q, Egashira K, Inoue S, et al: Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation. 105:1110–1115. 2002. View Article : Google Scholar : PubMed/NCBI
32	Pan P1, Fu H, Zhang L, et al: Angiotensin II upregulates the expression of placental growth factor in human vascular endothelial cells and smooth muscle cells. BMC Cell Biol. 11:362010. View Article : Google Scholar : PubMed/NCBI
33	Pupilli C, Lasagni L, Romagnani P, et al: Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J Am Soc Nephrol. 10:245–255. 1999.PubMed/NCBI
34	Kang YS, Park YG, Kim BK, et al: Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes. J Mol Endocrinol. 36:377–388. 2006. View Article : Google Scholar : PubMed/NCBI